Aerovate Therapeutics is starting a Phase 2b/3 clinical trial that will test AV-101, the company’s experimental inhaled formulation of imatinib, in people with pulmonary arterial hypertension (PAH). “We are excited and humbled to initiate this Phase 2b/Phase 3 trial of AV-101. Starting enrollment represents an important milestone for Aerovate Therapeutics and…
Beyond Air has announced that it is not expecting the U.S. Food and Drug Administration (FDA) to approve its LungFit PH device to treat persistent pulmonary hypertension of the newborn (PPHN) before the end of the year. Beyond Air filed an application with the FDA in late…
Treatment with the experimental medication KER-012 helped to prevent heart damage in a mouse model of pulmonary hypertension, new research shows. The findings were showcased by KER-012’s developer, Keros Therapeutics, at the American Heart Association (AHA) 2021 Scientific Sessions, held Nov. 13–15, according to a company press…
By analyzing how medications affect the genetic activity of cells, researchers developed a computational pipeline that may be useful in repurposing cancer treatments for use in other diseases. Leveraging this pipeline, the team identified two compounds, I-BET762 and BRD2889, that might be refined — more quickly and at lower cost…
Due to problems at a third-party facility, the U.S. Food and Drug Administration (FDA) has decided to not approve Tyvaso DPI, a dry powder inhaled formulation of treprostinil, at this time. According to United Therapeutics, the medication’s developer, the issue is expected to be dealt with soon. The company anticipates…
People with pulmonary hypertension (PH) who start treatment with opioids to manage pain after undergoing surgery are at high risk of continuing to take these addictive medications for longer than required, new research suggests. Indeed, hypertension was one of eight specifically identified “top risk factors” for “new persistent post-surgical…
The U.S. Food and Drug Administration (FDA) has cleared Tenax Therapeutics to begin clinical testing of its new oral formulation of imatinib in people with pulmonary arterial hypertension (PAH). The company is planning to conduct a small pharmacological study this year — and then launch a Phase 3…
Targeting a protein called p110a, a part of the PI3K family of enzymes, may be useful for preventing or even reversing pulmonary hypertension, research done in cells and rodent models showed. “Targeted inhibition of [p110a] offers a disease-modifying treatment approach, which is readily accessible by small molecule inhibitors and…
A lab version of an investigational treatment for bone disorders and pulmonary arterial hypertension (PAH), KER-012 prevented bone loss in a PAH rat model, its developer, Keros Therapeutics, reported. Separate preclinical data in a PAH rat model, presented by the company earlier this year, also demonstrated that KER-012 worked to…
Blocking the activity of a small RNA molecule called microRNA-30a eased alterations in heart structure and blood vessel architecture in mouse models of pulmonary arterial hypertension (PAH), a new study reports. Results also showed that this molecule is present at abnormally high levels in PAH patients, supporting its potential…
Many people with chronic thromboembolic pulmonary hypertension or CTEPH have a particular anatomical variation called May-Thurner anatomy, which may increase the risk of developing this rare disease type, according to researchers. A new study found this anomaly is very common in individuals with CTEPH, with nearly 30% of patients…
COVID-19 tends not to cause serious disease or death in children with pulmonary hypertension (PH), but its long-term consequences remain unknown, according to a study done at a center in Texas. The study, “Outcomes of COVID-19 Infection in pediatric pulmonary hypertension: a single-center experience,” was published in the…
Get regular updates to your inbox.